Insider sales and context
Richard Marshak, the Chief Commercial Officer at TriSalus Life Sciences, Inc. (NASDAQ: TLSI), executed a series of share sales totaling 3,457 common shares between March 11 and March 16, 2026. The transactions, recorded under transaction code "S", brought in a combined $14,209 and were completed at prices between $4.09 and $4.13 per share.
Breakdown of the trades shows 1,449 shares sold on March 11 at $4.13 per share, 1,589 shares on March 12 at $4.09 per share, and a final block of 419 shares on March 16 at $4.12 per share. Following those dispositions, Marshak is reported to directly hold 110,397 shares of TriSalus common stock.
Footnote on intent
The footnotes in the related SEC filing specify that the sales were completed to satisfy tax withholding obligations triggered by the vesting of restricted stock units. The filing explicitly notes these transactions do not constitute discretionary sales by Marshak.
Market position and recent performance
TriSalus shares were trading at $3.92 at the time of the notice. The stock has declined 45% year-to-date and is approximately 51% below its 52-week high of $7.95. Those price movements set the market backdrop for the disclosure of the insider transactions.
Operational and financial update
In corporate results, TriSalus reported fourth-quarter 2025 revenue of $13.2 million, a 60% increase year-over-year. Management attributed this revenue expansion to improved manufacturing efficiencies and a broadening of the company’s product portfolio. For the quarter, the company recorded a net operating loss of $3.3 million, an improvement from a $7.6 million operating loss in the same period a year earlier.
On a full-year basis, TriSalus reported fiscal 2025 revenue of $45 million, representing a 53% increase compared with fiscal 2024.
Analyst coverage and scientific progress
Following the earnings announcement, Jones Trading reiterated a Buy rating on TriSalus and kept a price target of $11.00. The firm also conducted a follow-up call with company management after the results were released.
Separately, TriSalus published preclinical research in the journal Frontiers in Oncology. The study evaluated delivery and biological activity of nelitolimod in liver tumor models using the company’s Pressure-Enabled Drug Delivery (PEDD) technology.
What this collection of developments shows
The combination of insider activity - clarified as tax-related - and recent operational updates provides a mixed snapshot: revenue growth and scientific progress on one hand, and continued operating losses and stock price decline on the other. The company’s actions and the analyst coverage noted in the filings and releases reflect ongoing efforts to advance both financial and technological positions.
Note: The sale transactions, valuation data, ownership totals, earnings figures, analyst action, and the preclinical publication are reported as stated in company filings and announcements.